Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The Burt Stem Cell Institute, led by Dr. Richard Burt, is a specialized clinical and research organization focused on autologous hematopoietic stem cell transplantation (HSCT) for the treatment of autoimmune diseases. Dr. Burt is a pioneer in the field, having conducted the first HSCTs for multiple sclerosis, systemic sclerosis, and Crohn's disease. The institute's therapeutic approach involves a non-myeloablative conditioning regimen designed to 'reset' the patient's immune system by eliminating self-reactive lymphocytes and re-populating the system with autologous stem cells. This platform has shown significant success in clinical trials, particularly in reversing disability in patients with relapsing-remitting multiple sclerosis. Currently operating out of Scripps Health in La Jolla, California, the institute continues to advance the clinical application of stem cell-based immunotherapy for a wide range of refractory immune-mediated conditions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Richard Burt.